Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy
Calvin D. De Louche, Ali Roghanian
JCI Insight (2022) Vol. 7, Iss. 2
Open Access | Times Cited: 21

Showing 21 citing articles:

Single-cell and spatial transcriptomics analysis of non-small cell lung cancer
Marco De Zuani, Haoliang Xue, Jun Sung Park, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 35
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
LILRB4 Checkpoint for Immunotherapy: Structure, Mechanism and Disease Targets
Zhiqing Xiang, Xiangli Yin, Leiyan Wei, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 187-187
Open Access | Times Cited: 8
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
Tobias Zeller, Sebastian Lutz, Ira A. Münnich, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 28
Macrophages as a Potential Immunotherapeutic Target in Solid Cancers
Alok Mishra, Shahid Banday, Ravi Bharadwaj, et al.
Vaccines (2022) Vol. 11, Iss. 1, pp. 55-55
Open Access | Times Cited: 28
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
Tobias Zeller, Ira A. Münnich, Roland Windisch, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Human leukocyte immunoglobulin-like receptors in health and disease
Silvia Redondo-García, Christopher Barritt, Charys Papagregoriou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3
Vincent C. Luca
Immunological Reviews (2025) Vol. 330, Iss. 1
Closed Access
Macrophages as Targets in Hepatocellular Carcinoma Therapy
Y. Liu, Zhengwei Mao, Yuan Ding, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 6, pp. 780-790
Open Access | Times Cited: 4
Exposure to per- and polyfluoroalkyl substances and high-throughput proteomics in Hispanic youth
Jiawen Chen, Jesse A. Goodrich, Douglas I. Walker, et al.
Environment International (2024) Vol. 186, pp. 108601-108601
Open Access | Times Cited: 4
Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis
Miao Xian, Qiang Wang, Liuling Xiao, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms
Alexander P. Simpson, Ali Roghanian, Robert J. Oldham, et al.
Cell Reports (2022) Vol. 40, Iss. 3, pp. 111099-111099
Open Access | Times Cited: 13
CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
Asa P. Y. Lau, Sharon S. Khavkine Binstock, Kelsie L. Thu
Cancers (2023) Vol. 15, Iss. 21, pp. 5229-5229
Open Access | Times Cited: 7
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity
David Bassan, Leehee Weinberger, Jason Yi, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 12, pp. e007426-e007426
Open Access | Times Cited: 6
IOS-1002, a Stabilized HLA-B57 Open Format, Exerts Potent Anti-Tumor Activity
Anahita Rafiei, Marco Gualandi, Chia-Lung Yang, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2902-2902
Open Access | Times Cited: 1
Markers of terminally differentiated T-cells as predictors of vascular health in renal transplant recipients and healthy adults
Silvia Lee, HuiJun Chih, Jacquita S. Affandi, et al.
Clinical Immunology (2023) Vol. 255, pp. 109760-109760
Open Access | Times Cited: 2
The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications
Alan W. Hodges, Rachel Dubuque, Shu‐Hsia Chen, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access
Target interactions for macrophage regulation: toward the development of therapeutics for cancer and inflammatory diseases
Etsuko Toda, Yuya Terashima
Translational and Regulatory Sciences (2024) Vol. 6, Iss. 1, pp. 28-36
Open Access
The Effect of Vitamin D Deficiency on Immune-Related Hub Genes: A Network Analysis Associated With Type 1 Diabetes
Safin Hussein, Fatemeh Bandarian, Najmeh Salehi, et al.
Cureus (2024)
Open Access
Human cytomegalovirus UL18 prevents priming of MHC-E– and MHC-II–restricted CD8 + T cells
Daniel Malouli, Husam Taher, Mandana Mansouri, et al.
Science Immunology (2024) Vol. 9, Iss. 100
Closed Access
Overall avidity declines in TCR repertoires during latent CMV but not EBV infection
Barbara Couturaud, Bastien Doix, Laura Carretero-Iglesia, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access
Page 1

Scroll to top